Open AccessAdenoviral Gene Therapy for Pancreatic Cancer: Where Do We Stand?
Author(s) -
Koert F.D. Kuhlmann,
Dirk J. Gouma,
John G. Wesseling
Publication year - 2008
Publication title -
digestive surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 69
eISSN - 1421-9983
pISSN - 0253-4886
DOI - 10.1159/000145981
Subject(s) - medicine , genetic enhancement , pancreatic cancer , viral vector , immune system , cancer , clinical trial , vector (molecular biology) , cancer research , oncology , immunology , gene , recombinant dna , biology , biochemistry
The prognosis of patients with pancreatic cancer is poor. This is mainly caused by the late diagnosis, the aggressive biology and the lack of effective treatment modalities. Adenoviral gene therapy has the potential to selectively treat both primary tumor and (micro)metastatic tissue.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom